摘要
目的分析高危型人乳头瘤状病毒(human papilloma virus,HPV)阳性患者宫颈做活组织病理检查及P16蛋白检测意义研究。方法选择本院2021年07月~2023年06月期间收治的以宫颈细胞病理学和HPV-DNA诊断为高危型HPV阳性患者76例作为研究对象。入院后均提供宫颈活组织病理检查,同时检测P16蛋白。分析宫颈活组织病理检查与P16蛋白的阳性检出情况。结果76例高危型HPV阳性患者宫颈活组织病理诊断结果示,慢性宫颈炎占比35.53%,高级别鳞状上皮内瘤变占比39.47%,宫颈癌占比25.00%。临床HPV分型检测显示HPV16型和52型及31型占比最高,分别为26.32%、15.79%和10.53%,以HPV35型和HPV59型最低,占比2.63%和1.32%(P<0.05)。统计P16蛋白阳性率,慢性宫颈炎81.48%,高级别鳞状上皮内瘤变93.33%,宫颈癌100.00%,P16蛋白诊断符合率90.79%(P>0.05)。P16蛋白与高危型HPV阳性宫颈活组织病理检查诊断结果具有正相关性。结论宫颈活组织病理检查可明确高危型HPV阳性患者的临床分型,P16蛋白与宫颈活组织病理检查结果具有相关性,可用于识别宫颈癌变风险。
Objective To analyze the significance of cervical biopsy and P16 protein detection in high-risk human papilloma virus(HPV)positive patients.Methods 76 cases of high-risk HPV-positive patients with cervical cytopathology and HPV-DNA diagnosis admitted to our hospital from July 2021 to June 2023 were selected as the study objects.After admission,cervical biopsy was performed and P16 protein was detected.Cervical biopsy and positive detection of P16 protein were analyzed.Results In 76 high-risk HPV-positive patients,chronic cervicitis accounted for 35.53%,high-grade squamous intraepithelial neoplasia accounted for 39.47%,and cervical cancer accounted for 25.00%.The clinical HPV typing test showed that the proportion of HPV16,52 and 31 was the highest,which was 26.32%,15.79%and 10.53%,respectively,and the proportion of HPV35 and HPV59 was the lowest,which was 2.63%and 1.32%(P<0.05).The positive rate of P16 protein was 81.48%for chronic cervicitis,93.33%for high-grade squamous intraepithelial neoplasia,100.00%for cervical cancer,and 90.79%(P>0.05).P16 protein was positively correlated with the diagnosis results of high-risk HPV positive cervical biopsy.Conclusions Cervical biopsy can determine the clinical classification of high-risk HPV-positive patients,and P16 protein is correlated with cervical biopsy results,which can be used to identify the risk of cervical cancer.
作者
王松
王桃阳
李俏然
WANG Song;WANG Taoyang;LI Qiaoran(Department of Pathology,Zhumadian Central Hospital,Zhumadian 463000,Henan,China)
出处
《航空航天医学杂志》
2024年第11期1290-1292,共3页
Journal of Aerospace medicine